olaparib,durvalumab,osimertinib,acalabrutinib
astrazeneca,merck
['calquence', 'lynparza', 'imfinzi', 'tagrisso', 'astrazeneca']
 grew @ ~30% cagr in #oncology in the last 5 years. the growth will continue to be driven by tagrisso, imfinzi, lynparza, and calquence with approvals in new indications #whatsnext #esmo22 follow us for more 
A healthcare-focused strategy consulting firm, providing bench-to-bedside decision support to pharmaceutical, biotech, and medical device companies